Predictable threats to public health through delaying universal access to innovative medicines for Hepatitis C: A pharmaceutical standpoint
The new interferon-free direct-acting antiviral (DAAs) treatment combinations have with the potential to provide a cure for Hepatitis C Virus patients and stop the pandemic, but their high prices keep treatment out of reach for most patients in Low- and Middle-Income countries, and the access strategies voluntarily put in place by some pharmaceutical companies remain insufficient to provide treatment to all those in need. This creates room for unregulated markets and pushes desperate patients...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Copyright holder:
- Ravinetto et al
- Copyright date:
Copyright © 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.